NVS vs JNJ
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NVS · Novartis AG$162.55 ▲ 0.38%
JNJ · Johnson & Johnson$276.22 ▲ 1.43%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NVS +31.7%
- JNJ +49.9%
Head to head
| Metric | NVS | JNJ |
|---|---|---|
| Price | $162.55 | $276.22 |
| Change today | ▲ 0.38% | ▲ 1.43% |
| Market cap | $307.00B | $664.95B |
| Return, 3 months | +3.7% | +6.0% |
| Return, year to date | +21.5% | +35.6% |
| Return, 1 year | +32.5% | +51.4% |
| P/E (TTM) | 31.0 | 42.0 |
| P/B | 8.2 | 8.2 |
| P/E percentile vs own 5y | 97th | 100th |
| Dividend yield | 2.92% | 1.91% |
| Revenue growth (YoY, latest qtr) | +4.7% | +5.9% |
| Net profit growth (YoY) | -69.6% | -95.9% |
| Gross margin | 74.9% | 67.6% |
| Operating margin | 25.2% | 25.7% |
| Net margin | 17.5% | 16.2% |
| Return on equity | 24.6% | – |
| Analyst target vs. price | +5.5% | +4.9% |
| Analyst buy share | 67% | 69% |
| RSI (14) | 65 | 59 |
| 30-day volatility | 25.9% | 30.6% |
| Max drawdown, 1 year | -16.2% | -11.0% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JNJ is the largest of the group by market value.
- JNJ has returned the most over the past year.
- NVS carries the lowest trailing P/E.
- NVS pays the highest dividend yield.
- JNJ is growing revenue fastest.
- NVS keeps the most profit per dollar of sales.
- NVS has been the calmest stock over the last 30 days.